Sichuan Kelun-Biotech Biopharmaceutical valuation
$398.40Change from previous close: −5.59%Absolute change: −$23.60
Valuation
The P/E ratio is 553.3. The average price target of 20 analysts is $617.60.
Data as of November 22, 2026
Sichuan Kelun-Biotech Biopharmaceutical compared with similar companies
Sichuan Kelun-Biotech Biopharmaceutical's Forward P/E: 121.7, +284% against the median of a group of 11 similar companies (31.7).
| Metric | Sichuan Kelun-Biotech Biopharmaceutical | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| Forward P/E | 121.7 | 31.7 | 22.2 – 41.7 | High |
| Price/book | 14.8 | 4.16 | 2.56 – 7.85 | High |
| Price/sales | 45.7 | 9.88 | 5.78 – 31.6 | High |
| Gross margin | 74.6% | 74.6% | 56.9% – 79.1% | Middle |
| Operating margin | -0.2% | 21.1% | 10.7% – 32.0% | Low |
| Net margin | 7.2% | 11.1% | 7.2% – 26.8% | Middle |
| ROE | 2.9% | 10.4% | 5.0% – 19.8% | Low |
| Debt/equity | 0.02 | 0.11 | 0.05 – 0.38 | Low |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $95.23B
- Enterprise value
- $88.21B
- P/E (trailing 12 months)
- 553.3
- EV/EBITDA
- 1,490.7
- EV/revenue
- 42.3
Profitability and growth
- ROA
- -0.0%
- ROIC
- -0.0%
- Revenue growth (year over year)
- 2.9%
- Earnings growth (year over year)
- -361.1%
Financial health
- Total cash
- $4.78B
- Total debt
- $81.35M
- Current ratio
- 6.34
- Quick ratio
- 5.98
- Altman Z-Score
- 55.8
- Piotroski F-Score
- 5.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $617.60
- Median price target
- $625.00
- High price target
- $765.30
- Low price target
- $520.00
- Analysts with a price target
- 20
- Consensus
- Strong buy
- Forward EPS
- $3.27
- EPS estimate, current year
- $0.81
Shares and trading
- Beta
- 0.10
- Average volume
- 694.16K
- Shares outstanding
- 176.82M
- Float
- 97.58M
- Institutional ownership
- 28.0%
- Insider ownership
- 58.9%
